Incidence and survival of children and young people with central nervous system embryonal tumours in the North of England, 1990–2013

Fairley, Lesley; Picton, Susan; McNally, Richard J.Q.; Bailey, Simon; McCabe, Martin G.; Feltbower, Richard

doi:10.1016/j.ejca.2016.03.083

Cited by 17 publications

(11 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Survival rates in the herein presented consecutive national Norwegian MB/CNS‐PNET material were in line with a similar study from Sweden, but lower than results from other countries (Canada and France) . One possible explanation is that the Canadian work did not include patients from the period 1974–1990.…”

Section: Discussionsupporting

confidence: 83%

“…Medulloblastoma (MB) and supratentorial primitive neuroectodermal tumor (CNS‐PNET) account for about 15%–20% and 2.5%, respectively, of malignant brain tumors in children. Altogether, these two comprise approximately 10%–15% of all pediatric brain tumors . Both entities are embryonal tumors, MB arising in the infratentorial and CNS‐PNET in the supratentorial brain.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor in Norway from 1974 through 2013: Unexplainable regional differences in survival

Stensvold

Myklebust

Cappelen

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background:A previous study based on Norwegian Cancer Registry data suggested regional differences in overall survival (OS) after treatment for medulloblastoma (MB) and supratentorial primitive neuroectodermal tumor (CNS-PNET) in Norway. The purpose of the present study was to confirm in an extended cohort whether there were regional differences in outcome or not, and if so try to identify possible explanations. Material and methods:Data from patients aged 0-20 years diagnosed with and treated for MB/CNS-PNET at all four university hospitals in Norway from 1974 to 2013 were collected and compared. Results: Of 266 identified patients, 251 fulfilled inclusion criteria. MB was diagnosed in 200 and CNS-PNET in 51 patients. Five-year OS and event-free survival (EFS) were 59% and 52%, respec-tively. There was a significant difference in five-year OS and EFS between MB and CNS-PNET patients; 62% versus 47% (P = 0.007) and 57% versus 35% (P < 0.001). In multivariable analysis, two factors were found to significantly contribute to improved five-year OS and EFS, whereas one factor contributed to improved five-year OS only. Gross total resection (GTR) versus non-GTR (hazard ratio [HR] 0.53, P = 0.003; HR 0.46, P < 0.001) and cerebrospinal irradiation (CSI) versus non-CSI (HR 0.24, P < 0.001; HR 0.28, P < 0.001) for both, and treatment outside Oslo University Hospital for OS only (HR 0.64, P = 0.048). Conclusion:Survival was comparable with data from other population-based studies, and the importance of GTR and CSI was confirmed. The cause for regional survival differences could not be identified. K E Y W O R D S

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Introductionmentioning

confidence: 99%

Children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor in Norway from 1974 through 2013: Unexplainable regional differences in survival

Stensvold

Myklebust

Cappelen

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Fairley et al . found an OS of 54% in 5 years for children under 14 years old in the U.K.[6] Similarly, Smoll, in 2012, calculating the cumulative relative survival estimate, found a 5-year OS and 10-year OS of 25%/25% and 56%/52% for infants and children, respectively. [22] The lack of information from Brazilian cohorts does not allow internal comparisons.…”

Section: Discussionmentioning

confidence: 99%

“…This led to a reduction in the risk of death by approximately 30%. [6] Nowadays, current treatment protocols include maximal safe tumor resection followed by radiotherapy in children older than 3 years old, and chemotherapy (CT) with cytotoxic agents, both according to risk stratification. For children under 3 years old, only CT with potent agents is allowed due to the possible damage caused by irradiation on an immature brain.…”

Section: Introductionmentioning

confidence: 99%

Survival and prognostic factors in childhood medulloblastoma: A Brazilian single center experience from 1995 to 2016

Bleil¹,

Bizzi

Bedin³

et al. 2019

Surgical Neurology International

View full text Add to dashboard Cite

Background: Medulloblastoma is the most common malignant brain tumor in the pediatric population. Despite prognosis improvement in the past two decades, one-third of the patients still remain incurable. New evidence suggests that medulloblastoma comprises four distinct entities; therefore, treatment de-escalation is required. The aim of this article is to evaluate epidemiological data from patients treated at our institution. The primary objective is to analyze overall survival (OS) and event-free survival (EFS) and the secondary objective is to identify prognostic factor from this cohort. Methods: We retrospectively analyzed 69 patients who underwent surgical resection for medulloblastoma among 423 children from the tumor registry data bank of Santo Antônio Children’s Hospital from 1995 to 2016. Kaplan–Meier method and Cox regression analysis were used to identify OS, EFS, and prognostic factors. Results: The 5-year OS and EFS rates found were 44.5% and 36.4%, respectively. The extent of resection and radiotherapy as adjuvant treatments was positively correlated to outcome while metastatic disease at diagnosis was negatively related to OS. Age younger than 3 years old did not have a worse outcome in our cohort. Conclusion: Similar results to population-based studies were found, but we still face difficulties due to living in a developing country. In the near future, we look forward to new diagnostic techniques that will enable us to classify medulloblastomas according to molecular subgroups.

show abstract

“…16 We observed that incidence of CNS tumours increased until 2002 and plateaued thereafter, similar to Australia. 13 Many studies found increases over the entire study period, 8,11,12,17,20 others found no increase, 14,16,19,32,35,42,43 or even a decrease. 35 We also found that incidence of epithelial neoplasms and melanomas increased over the entire study period, similar to the USA, 10,32 Australia, 13 and Korea.…”

Section: International Comparisonmentioning

confidence: 99%

Temporal trends in incidence of childhood cancer in Switzerland, 1985–2014

Sommer

Schindler

Redmond

et al. 2019

Cancer Epidemiology

View full text Add to dashboard Cite

Background: Incidence of childhood cancer increased in most countries worldwide, but the reasons are unclear. This study investigates trends in childhood cancer incidence in Switzerland from 1985 to 2014. Methods: We extracted data on all childhood cancer cases diagnosed at ages 0-14 years in Switzerland from the Swiss Childhood Cancer Registry. We included ICCC-3 main groups I-XII and calculated age-standardised, cumulative, and age-specific incidence for different diagnostic groups. We analysed trends in annual agestandardised incidence using JoinPoint regression models. Results: Over the study period from 1985-2014, 5104 of 5486 cancer diagnoses (93%) were microscopically verified. The proportion of children treated in paediatric cancer

show abstract

Incidence and survival of children and young people with central nervous system embryonal tumours in the North of England, 1990–2013

Abstract: Background: Medulloblastoma and primitive neuroectodermal tumours (PNET) are the

Cited by 17 publications

References 27 publications

Children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor in Norway from 1974 through 2013: Unexplainable regional differences in survival

Children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor in Norway from 1974 through 2013: Unexplainable regional differences in survival

Survival and prognostic factors in childhood medulloblastoma: A Brazilian single center experience from 1995 to 2016

Temporal trends in incidence of childhood cancer in Switzerland, 1985–2014

Contact Info

Product

Resources

About